Fast-Track-Designation-NASH Fast-Track-Designation-NASH Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
FOYA_Shanghai FOYA_Shanghai Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
We’re looking for SAP developers to join our Global IT Department We’re looking for SAP developers to join our Global IT Department Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Transforming Science Day Transforming Science Day How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Quality Quality At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Early careers Early careers At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
About Chronic Kidney Disease About Chronic Kidney Disease CKD is very common and often goes undetected due to its silent nature. Risk factors include high blood pressure and type 2 diabetes.
Yanina Donatini Yanina Donatini Yanina Donatini, Head of ITM&S Content Production, jumped at the chance to fulfill her dreams within the Information Technology division at Boehringer Ingelheim.
Really Digital, Mr Hach! Really Digital, Mr Hach! The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
RE-LY-trial-publication-10-year-anniversary RE-LY-trial-publication-10-year-anniversary Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Living Independence Living Independence Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Our Expectations Our Expectations We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
founding-member-of-QUTAC founding-member-of-QUTAC Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
The generalized pustular psoriasis (GPP) Forum 2023 The generalized pustular psoriasis (GPP) Forum 2023 An executive summary of the activities and key takeaways from the GPP Forum 2023
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Bees and biodiversity Bees and biodiversity At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments